CytoMed Therapeutics (NASDAQ: GDTC) director reports 2,469 ordinary shares on Form 3

Rhea-AI Filing Summary

CytoMed Therapeutics Ltd director Yew Chak Hua reported initial ownership of 2,469 Ordinary Shares, no par value per share. This Form 3 establishes his status as a director and shows a relatively small direct stake. The report does not indicate any recent purchases, sales, or option exercises, only current holdings.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Yew Chak Hua

Role null

Type	Security	Shares	Price	Value
holding	Ordinary Shares, no par value per share	--	--	--

Holdings After Transaction: Ordinary Shares, no par value per share — 2,469 shares (Direct, null)

Footnotes (1)

Key Figures

Director shareholdings: 2,469 shares Buy transactions: 0 transactions Sell transactions: 0 transactions +2 more

5 metrics

Director shareholdings 2,469 shares Total Ordinary Shares directly owned after reported holding entry

Buy transactions 0 transactions BuyCount in transactionSummary

Sell transactions 0 transactions SellCount in transactionSummary

Holding entries 1 entry HoldingEntries in transactionSummary

Unknown transaction records 1 record UnknownCount in transactionSummary

Key Terms

Ordinary Shares, no par value per share, direct ownership, reporting person, holding entry

4 terms

Ordinary Shares, no par value per share financial

"security_title: "Ordinary Shares, no par value per share""

direct ownership financial

"ownership_type: "direct" with ownership_code "D""

reporting person regulatory

""reportingPersons": [{"name": "Yew Chak Hua""

holding entry regulatory

"transaction_type: "holding" and holdingEntries: 1"

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Yew Chak Hua

(Last) (First) (Middle)

C/O CYTOMED THERAPEUTICS LIMITED

1 COMMONWEALTH LANE #08-22

(Street)

SINGAPORE 149544

(City) (State) (Zip)

SINGAPORE

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
CytoMed Therapeutics Ltd [ GDTC ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares, no par value per share	2,469	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Chak Hua Yew	05/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the CytoMed Therapeutics (GDTC) Form 3 show for Yew Chak Hua?

The Form 3 shows that director Yew Chak Hua directly owns 2,469 Ordinary Shares of CytoMed Therapeutics Ltd. It is an initial ownership report, not evidence of any recent share purchases or sales.

Is there any buy or sell activity in GDTC shares by Yew Chak Hua in this Form 3?

No, the Form 3 for Yew Chak Hua shows only a holding entry with 2,469 Ordinary Shares. The transaction data indicate no recorded buys, sells, exercises, gifts, or tax-related dispositions.

How many CytoMed Therapeutics (GDTC) shares does Yew Chak Hua hold after the reported Form 3 entry?

After the reported holding entry, Yew Chak Hua is shown as directly owning 2,469 Ordinary Shares of CytoMed Therapeutics Ltd. This figure reflects his position following the reported ownership status.

Does the CytoMed Therapeutics (GDTC) Form 3 include any derivative securities for Yew Chak Hua?

No, the insider data for Yew Chak Hua show an empty derivativeSummary. This means there are no options, warrants, or other derivative securities reported for him in this particular Form 3 submission.

What type of ownership does Yew Chak Hua report in CytoMed Therapeutics (GDTC)?

The Form 3 lists direct ownership of 2,469 Ordinary Shares for Yew Chak Hua. The ownership code is “D,” indicating the shares are held directly rather than through an indirect entity like a trust or partnership.